Novartis to Acquire Avidity Biosciences in $12 Billion Deal
Oct 26, 2025
Novartis, a global pharmaceutical company based in Switzerland, has agreed to buy Avidity Biosciences, a U.S. biotechnology firm, for $72 per share in cash. The total value of the deal is about $12 billion.
Avidity Biosciences is recognized for its innovation in RNA therapeutics, especially its Antibody Oligonucleotide Conjugates (AOCs™) platform. This acquisition will add three late-stage neuroscience programs to Novartis’s pipeline, focusing on genetic neuromuscular diseases.
Before the completion of the acquisition, Avidity will separate its early-stage precision cardiology programs into a new, publicly traded company named SpinCo.
The acquisition is expected to close in the first half of 2026, as long as SpinCo is successfully separated and other standard closing requirements are met. Novartis anticipates that this deal will support new product launches by 2030 and improve its sales growth outlook.
What is Avidity Biosciences known for?
Avidity Biosciences develops a new class of medicines called Antibody Oligonucleotide Conjugates (AOCs™), mainly focused on treating genetic neuromuscular diseases.
Why is Novartis buying Avidity Biosciences?
Novartis wants to strengthen its neuroscience division and bring new therapies to its pipeline, especially in genetic neuromuscular diseases.
What will happen to Avidity’s other projects?
Avidity's early-stage cardiology research will be placed into a new publicly traded company called SpinCo before the acquisition is completed.
When will the deal be completed?
The deal is expected to close in the first half of 2026, after all conditions are met.
Sources
Novartis nears $70-plus per share deal to acquire Avidity Biosciences, Bloomberg...
Reuters
Reuters
Swiss drugmaker Novartis AG is close to acquiring U.S. biotech Avidity Biosciences for over $70 per share, Bloomberg News reported on Sunday, citing a person familiar with the matter.
Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than...
CNBC
CNBC
Swiss pharmaceutical giant Novartis is nearing a deal to buy biotechnology company Avidity Biosciences for more than $70 a share, Bloomberg News reported.
Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics...
GlobeNewsWire
GlobeNewsWire
Ad hoc announcement pursuant to Art. 53 LR Transaction strengthens neuroscience franchise for Novartis with three late-stage programs that address genetic neuromuscular diseases Advances the Novartis xRNA strategy by adding a scientifically robust, muscle-directed, Antibody Oligonucleotide Conjugate...
Novartis to acquire Avidity Biosciences for $12 billion
Reuters
Reuters
Swiss drugmaker Novartis on Sunday said it agreed to acquire Avidity Biosciences for $12 billion.
Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG
Novartis to acquire Avidity for USD 72.00 per share in cash for total equity value of approximately USD 12.0 billion Avidity expects to separate its early-stage precision cardiology programs into a new company ("SpinCo") Closing expected in 1H2026 subject to completion of the separation of SpinCo f...
Novartis Deal Values Avidity Biosciences At $12 Billion
Barrons
Barrons
The acquisition would raise the 2024-2029 expected sales compound annual growth rate for Novartis to 6% from 5%, it said.
Novartis to acquire Avidity Biosciences for about $12B
New York Post
New York Post
Novartis has been proactively striking deals this year to address the impending patent cliff for some of its blockbuster drugs, including Entresto for heart failure, Xolair for asthma and Cosentyx for autoimmune diseases.
Novartis Agrees to Acquire Avidity Biosciences for $12 Billion
WSJ
WSJ
The Swiss pharmaceutical company says the purchase would complement its existing pipeline of treatments for neuromuscle disorders.
Novartis Agrees $12 Billion Biotech Deal for Avidity
Bloomberg Markets and Finance
Bloomberg Markets and Finance
Novartis agreed to buy biotechnology company Avidity in a deal valued at $12 billion, making it the Swiss drugmaker's biggest acquisition in more than a decade and adding several potential blockbuster treatments as generic competition looms for its current top-sellers. Sam Fazeli of Bloomberg Intell...
Novartis shares slip, Avidity soars after $12 billion biotech deal
Reuters
Reuters
Shares of Novartis fell 1% on Monday following news of the company's plans to acquire U.S. biotech Avidity Biosciences for about $12 billion, marking the Swiss drugmaker's largest acquisition under CEO Vas Narasimhan.
Trump's trade deals, Novartis acquires Avidity, Taco Bell's beverage push and mo...
CNBC
CNBC
President Donald Trump penned several trade agreements ahead of his expected meeting with China leader Xi Jinping later this week. Novartis announced it will buy Avidity Biosciences.
Novartis to acquire Avidity Biosciences in $12B deal
Proactive Investors
Proactive Investors
Novartis AG (ADR) (NYSE:NVS) announced it will acquire San Diego-based biopharmaceutical firm Avidity Biosciences (NASDAQ:RNA), which is developing RNA therapeutics for genetic neuromuscular diseases, in a transaction valued at approximately US$12 billion. The deal, unanimously approved by the board...
Is it too late to buy Avidity stock after Novartis deal?
Invezz
Invezz
Novartis (NYSE: NVS) revealed plans of acquiring Avidity Biosciences Inc (NASDAQ: RNA) in a $12 billion all-cash transaction – valuing each share of the biotech company at $72 on Monday. The announcement sent RNA shares soaring roughly 44% in a single session – indicating investor enthusiasm and con...
Why Avidity Biosciences And Dyne Therapeutics Stocks Soared 40% Monday
Investopedia
Investopedia
Shares of Avidity Biosciences (RNA) soared more than 40% Monday after Novartis (NVS) agreed to buy the U.S. biopharmaceutical firm for about $12 billion in cash to expand its RNA-based disease-fighting pipeline.
Avidity Biosciences Soars After $72 Per Share Novartis Takeover
Benzinga
Benzinga
Avidity Biosciences, Inc. (NASDAQ:RNA) stock surged after announcing a $12 billion all-cash acquisition by Novartis AG (NYSE:NVS), marking one of the largest biotech buyouts of the year.
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Avidi...
NEW YORK , Oct. 27, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is hea...
Why Avidity Biosciences Stock Blasted 42% Higher Today
The Motley Fool
The Motley Fool
It is being acquired for quite a meaty premium. The buyer is a top name in the global pharmaceuticals space.
Avidity Biosciences Investor Alert By The Former Attorney General Of Louisiana:...
Business Wire
Business Wire
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Avidity Biosciences, Inc. (NasdaqGM: RNA) to Novartis AG. Under the terms of the proposed transaction, sh...
Novartis CEO says pharma giant has the firepower for big M&A deals: 'Can never b...
CNBC
CNBC
The Swiss drugmaker announced its biggest deal in a decade on Sunday, as its set to buy Avidity Biosciences for about $12 billion. "We have adequate firepower to do deals like this and to bolster the growth profile of the company," the CEO told CNBC.
RNA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Avidity B...
Business Wire
Business Wire
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Avidity Biosciences, Inc. (NASDAQ: RNA) to Novartis for $72.00 per share in cash is fair to Avidity shareholders. Halper Sadeh encourages Avidity shareholders to click here to learn more ab...
Novartis CEO: We're never done with M&A
CNBC International TV
CNBC International TV
Vas Narasimhan, CEO of pharmaceuticals company, Novartis, discusses the company's latest $12 billion acquisition of Avidity Biosciences, and ongoing negotiations with the U.S. administration over potential pharmaceutical tariffs. ----- Subscribe: @CNBCInternationalLive Subscribe to CNBC Internationa...
Related Posts
Other News
Corporate Moves
View All
Meta Removes Instagram AI Image Feature Days After Launch Following Privacy Backlash
Jul 11, 2026
META
+5.97%
Meta has discontinued an AI image feature that let users generate or modify images using content from public Instagram accounts, just days after rolling it out. The company said the tool “missed the m...
Volkswagen Faces Protests as It Plans Major Job Cuts and Factory Closures in Germany
Jul 10, 2026
VOW
-1.3%
Volkswagen is facing protests in Germany as it prepares a major cost-cutting plan that could reshape its business at home. The company is expected to present proposals that may include cutting up to 1...
OpenAI Executive Fidji Simo Steps Down From Full-Time Role
Jul 10, 2026
OpenAI executive Fidji Simo is stepping down from her full-time role and will move into a part-time advisory position, according to multiple reports. Simo was the company’s chief of applications and o...
Product Launches
View All
Meta Stock Rises as Company Rolls Out Muse Image AI Tool
Jul 7, 2026
META
+5.97%
Meta Platforms shares climbed more than 1% on Tuesday, beating a weaker broader market, after the company said it is rolling out Muse Image, its first image-generation model from Meta Superintelligenc...
Amazon Says Leo Satellite Internet Service Will Launch Later This Year
Jul 3, 2026
AMZN
-0.69%
Amazon said it now has enough satellites in orbit to begin rolling out its Leo broadband internet service later this year. The company’s latest launch added 29 satellites and pushed the total in its c...
Robinhood Launches New Blockchain Network and Expands Crypto Offerings
Jul 2, 2026
HOOD
-2.73%
Robinhood shares rose after the company launched the public mainnet for Robinhood Chain, a new Layer 2 blockchain built with Arbitrum technology and designed for real-world assets and onchain financia...
Regulatory Actions
View All
Apple Sues OpenAI Over Alleged Trade Secret Theft and Breach of Contract
Jul 10, 2026
AAPL
-0.28%
Apple has filed a lawsuit against OpenAI in federal court in Northern California, accusing the AI company of trade secret theft and breach of contract. Apple says OpenAI used confidential information...
Circle Wins Final OCC Approval to Launch National Trust Bank, Shares Jump
Jul 10, 2026
CRCL
+4.97%
Circle Internet Group said it received final approval from the U.S. Office of the Comptroller of the Currency to establish a national trust bank called First National Digital Currency Bank, N.A., whic...
OpenAI Gets U.S. Approval for Broader GPT-5.6 Rollout
Jul 8, 2026
OpenAI has received U.S. approval for a broader rollout of its GPT-5.6 model, according to an Axios report citing a person familiar with the matter. The model had been under limits after U.S. official...
Earnings
View All
PepsiCo Stock Falls After Mixed Q2 Results as U.S. Sales Stay Flat
Jul 9, 2026
PEP
-0.35%
EZJ
+14.28%
PepsiCo shares fell about 5% to $135.34 after the company reported mixed second-quarter results. Investors had been watching the report closely ahead of the July 9 earnings release.
The company said...
Simply Good Foods Beats Q3 Estimates But Profit and Sales Fall From a Year Ago
Jul 9, 2026
SMPL
-1.84%
The Simply Good Foods Company reported fiscal third-quarter 2026 results that topped Wall Street estimates, but both sales and profit declined sharply from a year earlier. The company said net sales f...
PepsiCo Shares Fall After Slight Earnings Miss Despite Revenue Beat
Jul 9, 2026
PEP
-0.35%
PepsiCo reported fiscal second-quarter results that were mixed for investors. The company beat Wall Street estimates for revenue, but adjusted earnings per share came in slightly below expectations....
Stock Movements
View All
AstraZeneca Shares Fall Nearly 10% After Wainua Heart Trial Failure
Jul 9, 2026
AZN
-3.89%
AstraZeneca shares fell sharply on Thursday after the company said its Wainua treatment failed to meet the main goal in a late-stage trial for a serious heart condition. The stock dropped about 9.5% i...
Alibaba Shares Jump Nearly 10% as China Tech Stocks Rally Ahead of Earnings
Jul 8, 2026
BABA
+1.07%
Alibaba stock rose sharply on Wednesday, posting its strongest single-day gain in about 10 months. U.S.-listed shares climbed nearly 10% in early trading and traded around $106, helping lead a broader...
SpaceX Stock Falls Back Toward Its IPO Price as Valuation Concerns Grow
Jul 8, 2026
SPCX
-4.51%
SpaceX shares have slipped back to around their opening price of $150, erasing gains from the company’s blockbuster stock market debut. Investors who bought at the IPO have seen only a middling return...
Economy
View All
OPEC+ Raises Oil Output Again as Strait of Hormuz Traffic Recovers
Jul 6, 2026
OPEC+ agreed to raise oil production targets again, approving a further increase of 188,000 barrels per day from August. The move adds to similar increases for June and July as the group continues to...
ADP Says U.S. Private Payrolls Rose by 98,000 in June as Pay Increased 4.4%
Jul 1, 2026
ADP said private sector employment rose by 98,000 jobs in June, according to its National Employment Report. The report was produced by ADP Research in collaboration with the Stanford Digital Economy...
Oil Prices Fall as U.S.-Iran Deal Expectations Raise Supply Concerns
Jun 18, 2026
Oil prices fell as investors reacted to reports that a U.S.-Iran deal could reopen the Strait of Hormuz and bring more oil supply to the market. Brent and WTI both moved lower as traders priced in the...
Analyst Ratings
View All
Micron Stock Holds Steady as BofA Says the Selloff Creates a Buying Opportunity
Jul 9, 2026
MU
-1.24%
Micron shares steadied after a recent selloff in memory stocks, and Bank of America said the pullback may give investors a chance to buy the stock at a lower price.
The comments come as some investor...
Nvidia Stock Gets Bullish Backing From Bank of America as AI Leadership Stays in Focus
Jul 9, 2026
NVDA
+4.03%
Nvidia stock edged up less than 0.5% on Wednesday as investors continued to buy the dip in large-cap tech. The move came after Bank of America reiterated its Buy rating on the chipmaker and kept a bul...
Figma Shares Rise After Bank of America Reinstates Buy Rating and Says AI Could Help Growth
Jul 8, 2026
FIG
-5.17%
Figma shares rose on Tuesday after Bank of America reinstated coverage of the design software company with a Buy rating and a $30 price target. The stock moved higher by more than 6% to about $23 in a...
Mergers & Acquisitions
View All
Vertex Pharmaceuticals to Buy Crinetics in $10 Billion Cash Deal
Jul 6, 2026
CRNX
-0.05%
VRTX
-2.24%
Vertex Pharmaceuticals has agreed to buy Crinetics Pharmaceuticals in a deal valued at about $10 billion in equity. Vertex will pay $85.00 per share in cash under the definitive agreement announced Mo...
Lockheed Martin to Acquire Ultra Maritime in $3.45 Billion Deal
Jul 6, 2026
LMT
+0.96%
Lockheed Martin said it has signed a definitive agreement to buy Ultra Maritime for $3.45 billion.
Ultra Maritime is a global defense company focused on advanced undersea warfare and anti-submarine w...
Solstice Advanced Materials Agrees to Buy Element Solutions in $14.5 Billion Deal
Jul 6, 2026
ESI
-1.85%
SOLS
-2.39%
Solstice Advanced Materials, the Honeywell spinoff, said it will buy specialty chemicals maker Element Solutions in a cash-and-stock deal valued at about $14.5 billion including debt. The companies sa...
IPO
View All
SK Hynix Starts Nasdaq Listing for $28 Billion Share Sale as Demand Tops Supply
Jul 9, 2026
SK Hynix has launched a U.S. listing aimed at raising about $28 billion, with pricing expected this week. If completed at that size, the deal would rank as the second-largest equity offering ever, beh...
SK Hynix Plans About $28 Billion U.S. IPO to Tap AI Demand
Jul 6, 2026
SK Hynix plans to launch a U.S. initial public offering that could raise about $28 billion, according to its regulatory filing. The South Korean memory chipmaker is using the listing to tap strong inv...
Uber-Backed Lime Raises About $167 Million in U.S. IPO as Shares Rise on Nasdaq Debut
Jul 1, 2026
Uber-backed micromobility company Lime raised about $167 million in its U.S. initial public offering, according to the source reports. The company’s shares rose 8% in their Nasdaq debut, giving Lime a...
